Iovance Biotherapeutics, Inc. (IOVA) financial statements (2021 and earlier)

Company profile

Business Address 999 SKYWAY ROAD
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:635720777251307362404
Cash and cash equivalents676816153143977
Short-term investments562646611193293323327
Other undisclosed cash, cash equivalents, and short-term investments6666 0(0)
Other undisclosed current assets1455957
Total current assets:636724783256316367411
Noncurrent Assets
Operating lease, right-of-use asset551179111412
Property, plant and equipment59391914964
Other noncurrent assets13333333
Other undisclosed noncurrent assets6666555
Total noncurrent assets:132593532282825
TOTAL ASSETS:768782818288345396436
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities49574933322626
Accounts payable14251011161013
Accrued liabilities35323923161614
Debt  66787
Other undisclosed current liabilities67     
Total current liabilities:55645540393534
Noncurrent Liabilities
Long-term debt and lease obligation45423465
Operating lease, liability45423465
Liabilities, other than long-term debt12222200
Other liabilities12222200
Total noncurrent liabilities:57645765
Total liabilities:112705945464139
Stockholders' equity
Stockholders' equity attributable to parent, including:656712758243299355397
Common stock0000000
Additional paid in capital1,4871,4731,46188386900
Accumulated other comprehensive income00010862855
Accumulated deficit(830)(762)(703)(640)(571)(507)(458)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:656712758243299355397
TOTAL LIABILITIES AND EQUITY:768782818288345396436

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(69)(59)(64)(71)(65)(52)(50)
Operating loss:(69)(59)(64)(71)(65)(52)(50)
Nonoperating income
(Investment Income, Nonoperating)
0011223
Net loss available to common stockholders, diluted:(68)(59)(63)(70)(64)(49)(48)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(68)(59)(63)(70)(64)(49)(48)
Comprehensive loss:(68)(59)(63)(70)(64)(49)(48)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)(1)1(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(69)(59)(64)(69)(64)(50)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: